Kirtland Hills Capital Management LLC Has $2.02 Million Stock Holdings in Danaher Co. (NYSE:DHR)

Kirtland Hills Capital Management LLC increased its position in Danaher Co. (NYSE:DHR) by 0.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,254 shares of the conglomerate’s stock after purchasing an additional 58 shares during the quarter. Danaher makes up 0.9% of Kirtland Hills Capital Management LLC’s portfolio, making the stock its 23rd biggest position. Kirtland Hills Capital Management LLC’s holdings in Danaher were worth $2,017,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the business. Fort Pitt Capital Group LLC increased its position in shares of Danaher by 3.2% in the 3rd quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate’s stock valued at $66,194,000 after buying an additional 7,421 shares in the last quarter. Good Life Advisors LLC bought a new stake in shares of Danaher during the third quarter worth approximately $217,000. Oak Thistle LLC acquired a new position in Danaher in the 2nd quarter valued at $363,000. Harvest Portfolios Group Inc. increased its position in Danaher by 1.2% during the third quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate’s stock worth $56,233,000 after acquiring an additional 2,465 shares during the period. Finally, Diversified Trust Co raised its position in shares of Danaher by 75.4% in the second quarter. Diversified Trust Co now owns 4,360 shares of the conglomerate’s stock valued at $1,090,000 after buying an additional 1,874 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Trading Up 0.3 %

NYSE:DHR opened at $230.76 on Wednesday. The company has a 50 day simple moving average of $260.45 and a two-hundred day simple moving average of $260.32. The company has a market cap of $166.67 billion, a PE ratio of 44.04, a price-to-earnings-growth ratio of 4.24 and a beta of 0.85. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. Danaher Co. has a 12 month low of $207.63 and a 12 month high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the prior year, the business earned $2.02 earnings per share. Danaher’s revenue for the quarter was up 3.1% compared to the same quarter last year. Research analysts forecast that Danaher Co. will post 7.51 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.47%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Wall Street Analyst Weigh In

DHR has been the subject of several recent analyst reports. KeyCorp upped their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Robert W. Baird lowered their target price on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Stephens reiterated an “overweight” rating and issued a $315.00 price objective on shares of Danaher in a research note on Wednesday, October 23rd. Bank of America raised their price objective on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Finally, TD Cowen lifted their target price on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $287.16.

Insider Activity

In related news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This represents a 18.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 10.90% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.